Work

CYP2D6 Metabolizer Status Does Not Predict Response or Tolerability of Low-Dose Nortriptyline for Irritable Bowel Syndrome With Diarrhea

Year: 2026

Type: article

Abstract: Neuromodulators, including tricyclic antidepressants (TCAs), have long been used to treat irritable bowel syndrome with diarrhea (IBS-D),1,2 but clinical response to TCAs is not clearly related to dosage.3 Interindividual variations in adverse events and efficacy may be at least partially attributed to variability in drug plasma concentrations.4 Nortriptyline, a TCA commonly used in IBS-D, is primarily metabolized by CYP2D6. Genotype-inferred phenotype of CYP2D6 can classify patients into different metabolizer classes.

Source: Gastro Hep Advances

DOI: 10.1016/j.gastha.2026.101111

Authors: Kyle Staller, Jenna Clukey, Elizabeth N. Madva, Brian C. Healy, Minyi Lee, Manish K. Gala

Institutions: Harvard University, Massachusetts General Hospital

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000